Kura Oncology (NASDAQ:KURA) Shares Gap Down Following Analyst Downgrade

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price gapped down prior to trading on Thursday after Bank of America lowered their price target on the stock from $36.00 to $29.00. The stock had previously closed at $15.91, but opened at $11.80. Bank of America currently has a buy rating on the stock. Kura Oncology shares last traded at $9.78, with a volume of 3,092,133 shares trading hands.

KURA has been the topic of several other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Thursday. HC Wainwright lifted their price objective on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday. Jefferies Financial Group decreased their price target on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $29.38.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its position in Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares during the period. Vanguard Group Inc. boosted its stake in shares of Kura Oncology by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after purchasing an additional 28,212 shares during the period. Sofinnova Investments Inc. grew its holdings in Kura Oncology by 64.4% during the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares in the last quarter. Armistice Capital LLC lifted its holdings in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after buying an additional 302,000 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Kura Oncology during the first quarter valued at about $110,000.

Kura Oncology Stock Performance

The firm has a market capitalization of $839.85 million, a PE ratio of -4.66 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a 50-day moving average price of $18.08 and a 200-day moving average price of $19.76.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.